AARD vs CUBE · $284.4M cap vs P/E 25, rev $1.07B
Aardvark Therapeutics, Inc. Common Stock (AARD) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Aardvark Therapeutics, Inc. Common Stock (AARD) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
AARD does not have a complete income-statement cache yet.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
AARD currently screens at market cap $284.4M. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the AARD and CUBE stock pages for the full models.
Not investment advice.